Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 385

1.

Divergent Function of Programmed Death-Ligand 1 in Donor Tissue versus Recipient Immune System in a Murine Model of Bronchiolitis Obliterans.

Schütte-Nütgen K, Boenisch O, Harrach H, Casey A, Guleria I, Najafian N, Sayegh MH, Gerard CJ, Subramaniam M.

Am J Pathol. 2017 Jun;187(6):1368-1379. doi: 10.1016/j.ajpath.2017.02.007. Epub 2017 Apr 17.

PMID:
28427861
2.

Use of polyclonal/monoclonal antibody therapies in transplantation.

Yeung MY, Gabardi S, Sayegh MH.

Expert Opin Biol Ther. 2017 Mar;17(3):339-352. doi: 10.1080/14712598.2017.1283400. Epub 2017 Jan 30. Review.

PMID:
28092486
3.

Live Images of Donor Dendritic Cells Trafficking via CX3CR1 Pathway.

Ueno T, Kim P, McGrath MM, Yeung MY, Shimizu T, Jung K, Sayegh MH, Chandraker AK, Abdi R, Yun SH.

Front Immunol. 2016 Oct 14;7:412. eCollection 2016.

4.

Imaging cell biology in transplantation.

Ueno T, Jung K, Yeung MY, McGrath MM, Shimizu T, Kim P, Sayegh MH, Chandraker A, Yun SH.

Transpl Int. 2016 Dec;29(12):1349-1351. doi: 10.1111/tri.12852. Epub 2016 Sep 29. No abstract available.

5.

Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients.

Javaheri A, Molina M, Zamani P, Rodrigues A, Novak E, Chambers S, Stutman P, Maslanek W, Williams M, Lilly SM, Heeger P, Sayegh MH, Chandraker A, Briscoe DM, Daly KP, Starling R, Ikle D, Christie J, Rame JE, Goldberg LR, Billheimer J, Rader DJ.

J Heart Lung Transplant. 2016 Nov;35(11):1295-1302. doi: 10.1016/j.healun.2016.06.022. Epub 2016 Jul 15.

6.

The Limits of Linked Suppression for Regulatory T Cells.

Ito T, Yamada A, Batal I, Yeung MY, McGrath MM, Sayegh MH, Chandraker A, Ueno T.

Front Immunol. 2016 Mar 9;7:82. doi: 10.3389/fimmu.2016.00082. eCollection 2016. Review.

7.

ABCB5 Identifies Immunoregulatory Dermal Cells.

Schatton T, Yang J, Kleffel S, Uehara M, Barthel SR, Schlapbach C, Zhan Q, Dudeney S, Mueller H, Lee N, de Vries JC, Meier B, Vander Beken S, Kluth MA, Ganss C, Sharpe AH, Waaga-Gasser AM, Sayegh MH, Abdi R, Scharffetter-Kochanek K, Murphy GF, Kupper TS, Frank NY, Frank MH.

Cell Rep. 2015 Sep 8;12(10):1564-74. doi: 10.1016/j.celrep.2015.08.010. Epub 2015 Aug 28.

8.

Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens.

Kleffel S, Vergani A, Tezza S, Ben Nasr M, Niewczas MA, Wong S, Bassi R, D'Addio F, Schatton T, Abdi R, Atkinson M, Sayegh MH, Wen L, Wasserfall CH, O'Connor KC, Fiorina P.

Diabetes. 2015 Jan;64(1):158-71. doi: 10.2337/db13-1639. Epub 2014 Sep 3.

9.

Role of podocyte B7-1 in diabetic nephropathy.

Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, D'Addio F, Chin M, Tezza S, Ben Nasr M, Mattinzoli D, Ikehata M, Corradi D, Schumacher V, Buvall L, Yu CC, Chang JM, La Rosa S, Finzi G, Solini A, Vincenti F, Rastaldi MP, Reiser J, Krolewski AS, Mundel PH, Sayegh MH.

J Am Soc Nephrol. 2014 Jul;25(7):1415-29. doi: 10.1681/ASN.2013050518. Epub 2014 Mar 27.

10.

TIM4 Regulates the Anti-Islet Th2 Alloimmune Response.

Vergani A, Gatti F, Lee KM, D'Addio F, Tezza S, Chin M, Bassi R, Tian Z, Wu E, Maffi P, Ben Nasr M, Kim JI, Secchi A, Markmann JF, Rothstein DM, Turka LA, Sayegh MH, Fiorina P.

Cell Transplant. 2015;24(8):1599-1614. doi: 10.3727/096368914X678571. Epub 2014 Mar 7.

11.

Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes.

Kochupurakkal NM, Kruger AJ, Tripathi S, Zhu B, Adams LT, Rainbow DB, Rossini A, Greiner DL, Sayegh MH, Wicker LS, Guleria I.

PLoS One. 2014 Feb 28;9(2):e89561. doi: 10.1371/journal.pone.0089561. eCollection 2014.

12.

Targeting CD28 to prevent transplant rejection.

Yeung MY, Najafian N, Sayegh MH.

Expert Opin Ther Targets. 2014 Feb;18(2):225-42. doi: 10.1517/14728222.2014.863875. Epub 2013 Dec 12. Review.

PMID:
24329604
13.

Calcineurin inhibitors: 40 years later, can't live without ...

Azzi JR, Sayegh MH, Mallat SG.

J Immunol. 2013 Dec 15;191(12):5785-91. doi: 10.4049/jimmunol.1390055.

14.

T-cell co-stimulatory blockade in transplantation: two steps forward one step back!

Riella LV, Sayegh MH.

Expert Opin Biol Ther. 2013 Nov;13(11):1557-68. doi: 10.1517/14712598.2013.845661. Epub 2013 Oct 1. Review.

PMID:
24083381
15.

Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.

Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A, Munn DH, Murphy WJ, Azuma M, Yagita H, Fife BT, Sayegh MH, Najafian N, Socie G, Ahmed R, Freeman GJ, Sharpe AH, Blazar BR.

Blood. 2013 Oct 24;122(17):3062-73. doi: 10.1182/blood-2013-05-500801. Epub 2013 Sep 12.

16.

CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.

D'Addio F, Ueno T, Clarkson M, Zhu B, Vergani A, Freeman GJ, Sayegh MH, Ansari MJ, Fiorina P, Habicht A.

PLoS One. 2013 Apr 4;8(4):e60391. doi: 10.1371/journal.pone.0060391. Print 2013.

17.

Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection.

Vergani A, Fotino C, D'Addio F, Tezza S, Podetta M, Gatti F, Chin M, Bassi R, Molano RD, Corradi D, Gatti R, Ferrero ME, Secchi A, Grassi F, Ricordi C, Sayegh MH, Maffi P, Pileggi A, Fiorina P.

Diabetes. 2013 May;62(5):1665-75. doi: 10.2337/db12-0242. Epub 2013 Jan 11.

18.

Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7.

Vergani A, Tezza S, D'Addio F, Fotino C, Liu K, Niewczas M, Bassi R, Molano RD, Kleffel S, Petrelli A, Soleti A, Ammirati E, Frigerio M, Visner G, Grassi F, Ferrero ME, Corradi D, Abdi R, Ricordi C, Sayegh MH, Pileggi A, Fiorina P.

Circulation. 2013 Jan 29;127(4):463-75. doi: 10.1161/CIRCULATIONAHA.112.123653. Epub 2012 Dec 18.

19.

Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses.

Ueno T, Yeung MY, McGrath M, Yang S, Zaman N, Snawder B, Padera RF, Magee CN, Gorbatov R, Hashiguchi M, Azuma M, Freeman GJ, Sayegh MH, Najafian N.

Eur J Immunol. 2012 Sep;42(9):2343-53. doi: 10.1002/eji.201242501.

20.

Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model.

Riella LV, Liu T, Yang J, Chock S, Shimizu T, Mfarrej B, Batal I, Xiao X, Sayegh MH, Chandraker A.

Am J Transplant. 2012 Apr;12(4):846-55. doi: 10.1111/j.1600-6143.2011.03929.x. Epub 2012 Feb 2.

21.

Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo- and autoimmune responses.

Carvello M, Petrelli A, Vergani A, Lee KM, Tezza S, Chin M, Orsenigo E, Staudacher C, Secchi A, Dunussi-Joannopoulos K, Sayegh MH, Markmann JF, Fiorina P.

Diabetes. 2012 Jan;61(1):155-65. doi: 10.2337/db11-0684. Epub 2011 Nov 10.

22.

Immune profile of pediatric renal transplant recipients following alemtuzumab induction.

De Serres SA, Mfarrej BG, Magee CN, Benitez F, Ashoor I, Sayegh MH, Harmon WE, Najafian N.

J Am Soc Nephrol. 2012 Jan;23(1):174-82. doi: 10.1681/ASN.2011040360. Epub 2011 Nov 3.

23.

IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response.

Petrelli A, Carvello M, Vergani A, Lee KM, Tezza S, Du M, Kleffel S, Chengwen L, Mfarrej BG, Hwu P, Secchi A, Leonard WJ, Young D, Sayegh MH, Markmann JF, Zajac AJ, Fiorina P.

Diabetes. 2011 Dec;60(12):3223-34. doi: 10.2337/db11-0880. Epub 2011 Oct 19.

24.

Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance.

Zhao X, Boenisch O, Yeung M, Mfarrej B, Yang S, Turka LA, Sayegh MH, Iacomini J, Yuan X.

Am J Transplant. 2012 Jan;12(1):90-101. doi: 10.1111/j.1600-6143.2011.03770.x. Epub 2011 Oct 12.

25.

The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance.

D'Addio F, Riella LV, Mfarrej BG, Chabtini L, Adams LT, Yeung M, Yagita H, Azuma M, Sayegh MH, Guleria I.

J Immunol. 2011 Nov 1;187(9):4530-41. doi: 10.4049/jimmunol.1002031. Epub 2011 Sep 26.

26.

Role of nuclear factor of activated T cell (NFAT) transcription factors in skin and vascularized cardiac allograft rejection.

Ueno T, Yamada A, Ito T, Yeung MY, Gorbatov R, Shimizu T, Abdi R, Sayegh MH, Auchincloss H Jr, Najafian N.

Transplantation. 2011 Sep 15;92(5):e26-7. doi: 10.1097/TP.0b013e318228061c. No abstract available.

PMID:
21866037
27.

Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice.

Ding Q, Yeung M, Camirand G, Zeng Q, Akiba H, Yagita H, Chalasani G, Sayegh MH, Najafian N, Rothstein DM.

J Clin Invest. 2011 Sep;121(9):3645-56. doi: 10.1172/JCI46274. Epub 2011 Aug 8.

28.

T-cell co-stimulatory blockade in kidney transplantation: back to the bench.

Riella LV, Sayegh MH.

Kidney Int Suppl (2011). 2011 Aug;1(2):25-30.

29.

The novel role of SERPINB9 in cytotoxic protection of human mesenchymal stem cells.

El Haddad N, Moore R, Heathcote D, Mounayar M, Azzi J, Mfarrej B, Batal I, Ting C, Atkinson M, Sayegh MH, Ashton-Rickardt PG, Abdi R.

J Immunol. 2011 Sep 1;187(5):2252-60. doi: 10.4049/jimmunol.1003981. Epub 2011 Jul 27.

30.

The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.

Paterson AM, Brown KE, Keir ME, Vanguri VK, Riella LV, Chandraker A, Sayegh MH, Blazar BR, Freeman GJ, Sharpe AH.

J Immunol. 2011 Aug 1;187(3):1097-105. doi: 10.4049/jimmunol.1003496. Epub 2011 Jun 22.

31.

The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo.

Yang J, Riella LV, Chock S, Liu T, Zhao X, Yuan X, Paterson AM, Watanabe T, Vanguri V, Yagita H, Azuma M, Blazar BR, Freeman GJ, Rodig SJ, Sharpe AH, Chandraker A, Sayegh MH.

J Immunol. 2011 Aug 1;187(3):1113-9. doi: 10.4049/jimmunol.1100056. Epub 2011 Jun 22.

32.

Costimulatory pathways in transplantation.

Pilat N, Sayegh MH, Wekerle T.

Semin Immunol. 2011 Aug;23(4):293-303. doi: 10.1016/j.smim.2011.04.002. Epub 2011 May 26.

33.

Anti-CD3 mAb treatment cures PDL1-/-.NOD mice of diabetes but precipitates fatal myocarditis.

Mfarrej B, Keir M, Dada S, Trikudanathan S, Sayegh MH, Sharpe AH, Guleria I.

Clin Immunol. 2011 Jul;140(1):47-53. doi: 10.1016/j.clim.2011.03.011. Epub 2011 Mar 24.

34.

Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts.

Riella LV, Watanabe T, Sage PT, Yang J, Yeung M, Azzi J, Vanguri V, Chandraker A, Sharpe AH, Sayegh MH, Najafian N.

Am J Transplant. 2011 Apr;11(4):832-40. doi: 10.1111/j.1600-6143.2011.03451.x. Epub 2011 Mar 14.

35.

Donor antioxidant strategy prolongs cardiac allograft survival by attenuating tissue dendritic cell immunogenicity(†).

Jurewicz M, Ueno T, Azzi J, Tanaka K, Murayama T, Yang S, Sayegh MH, Niimi M, Abdi R.

Am J Transplant. 2011 Feb;11(2):348-55. doi: 10.1111/j.1600-6143.2010.03360.x. Epub 2010 Dec 23.

36.

Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1.

Fiorina P, Jurewicz M, Vergani A, Petrelli A, Carvello M, D'Addio F, Godwin JG, Law K, Wu E, Tian Z, Thoma G, Kovarik J, La Rosa S, Capella C, Rodig S, Zerwes HG, Sayegh MH, Abdi R.

J Immunol. 2011 Jan 1;186(1):121-31. doi: 10.4049/jimmunol.1000799. Epub 2010 Dec 3.

37.

Chronic renal allograft dysfunction (CAD): new frontiers. Introduction.

Sayegh MH.

Kidney Int Suppl. 2010 Dec;(119):S1. doi: 10.1038/ki.2010.415. No abstract available.

PMID:
21116309
38.

Mesenchymal stem cells express serine protease inhibitor to evade the host immune response.

El Haddad N, Heathcote D, Moore R, Yang S, Azzi J, Mfarrej B, Atkinson M, Sayegh MH, Lee JS, Ashton-Rickardt PG, Abdi R.

Blood. 2011 Jan 27;117(4):1176-83. doi: 10.1182/blood-2010-06-287979. Epub 2010 Nov 12.

39.

Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes.

Jurewicz M, Yang S, Augello A, Godwin JG, Moore RF, Azzi J, Fiorina P, Atkinson M, Sayegh MH, Abdi R.

Diabetes. 2010 Dec;59(12):3139-47. doi: 10.2337/db10-0542. Epub 2010 Sep 14.

40.

A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice.

Vergani A, D'Addio F, Jurewicz M, Petrelli A, Watanabe T, Liu K, Law K, Schuetz C, Carvello M, Orsenigo E, Deng S, Rodig SJ, Ansari JM, Staudacher C, Abdi R, Williams J, Markmann J, Atkinson M, Sayegh MH, Fiorina P.

Diabetes. 2010 Sep;59(9):2253-64. doi: 10.2337/db09-1264.

41.

A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model.

D'Addio F, Yuan X, Habicht A, Williams J, Ruzek M, Iacomini J, Turka LA, Sayegh MH, Najafian N, Ansari MJ.

Transplantation. 2010 Aug 15;90(3):260-9.

42.

Induction of transplantation tolerance to fully mismatched cardiac allografts by T cell mediated delivery of alloantigen.

Tian C, Yuan X, Jindra PT, Bagley J, Sayegh MH, Iacomini J.

Clin Immunol. 2010 Aug;136(2):174-87. doi: 10.1016/j.clim.2010.04.012. Epub 2010 May 8.

43.

A novel in vivo regulatory role of P-glycoprotein in alloimmunity.

Izawa A, Schatton T, Frank NY, Ueno T, Yamaura K, Pendse SS, Margaryan A, Grimm M, Gasser M, Waaga-Gasser AM, Sayegh MH, Frank MH.

Biochem Biophys Res Commun. 2010 Apr 9;394(3):646-52. doi: 10.1016/j.bbrc.2010.03.040. Epub 2010 Mar 15.

44.

Understanding how Tregs are regulated: therapeutic implications.

Yuan X, Sayegh MH, Iacomini J.

Transplantation. 2009 Nov 27;88(10):1159-60. doi: 10.1097/TP.0b013e3181bc236f. No abstract available.

PMID:
19935368
45.

Transplant nephrectomy improves survival following a failed renal allograft.

Ayus JC, Achinger SG, Lee S, Sayegh MH, Go AS.

J Am Soc Nephrol. 2010 Feb;21(2):374-80. doi: 10.1681/ASN.2009050480. Epub 2009 Oct 29.

46.

Paradoxical functions of B7: CD28 costimulation in a MHC class II-mismatched cardiac transplant model.

Yang J, Riella LV, Boenisch O, Popoola J, Robles S, Watanabe T, Vanguri V, Yuan X, Guleria I, Turka LA, Sayegh MH, Chandraker A.

Am J Transplant. 2009 Dec;9(12):2837-44. doi: 10.1111/j.1600-6143.2009.02839.x. Epub 2009 Oct 21.

47.

Clinical transplantation tolerance: a myth no more, but...

Azzi J, Sayegh MH.

Am J Kidney Dis. 2009 Dec;54(6):1005-11. doi: 10.1053/j.ajkd.2009.08.005. Epub 2009 Oct 9.

PMID:
19819055
48.

Immunosuppressive drugs and Tregs: a critical evaluation!

De Serres SA, Sayegh MH, Najafian N.

Clin J Am Soc Nephrol. 2009 Oct;4(10):1661-9. doi: 10.2215/CJN.03180509. Epub 2009 Aug 20. Review.

49.

Regulatory T cells in transplantation: what we know and what we do not know.

Yeung MY, Sayegh MH.

Transplant Proc. 2009 Jul-Aug;41(6 Suppl):S21-6. doi: 10.1016/j.transproceed.2009.06.093. Epub 2009 Jul 10.

PMID:
19651291
50.

Dual effects of the alloresponse by Th1 and Th2 cells on acute and chronic rejection of allotransplants.

Illigens BM, Yamada A, Anosova N, Dong VM, Sayegh MH, Benichou G.

Eur J Immunol. 2009 Nov;39(11):3000-9. doi: 10.1002/eji.200838980.

Supplemental Content

Loading ...
Support Center